James V. Cassella
James V. Cassella has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Christine M. Mack
Neurogen Corporation, Branford, CT 06405, USA
2 shared publicationsMarlys Hammond
Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Groton, CT 06340, USA
2 shared publications- Natasha Atanaskova Mesinkovska
Department of Dermatology, University of California, Irvine, Irvine, California
2 shared publications Paul A. DaSilva-Jardine
Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Groton, CT 06340, USA
2 shared publicationsRalph W. Stevenson
Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Groton, CT 06340, USA
2 shared publications- Richard Elliott
Newcastle University
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 23 July 2024
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 91 (5) , 880-888
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- 23 July 2024
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 91 (5) , 880-888
Top Cited PapersOpen AccessEfficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- 1 November 2020
- Published by Elsevier in Journal of Investigative Dermatology Symposium Proceedings
- Vol. 20 (1) , S62-S68
Burden of Illness in Alopecia Areata: A Cross-Sectional Online Survey Study
- 1 November 2020
- Published by Elsevier in Journal of Investigative Dermatology Symposium Proceedings
- Vol. 20 (1) , S62-S68
Burden of Illness in Alopecia Areata: A Cross-Sectional Online Survey Study
- 1 June 2016
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 15, S22
WS13.6 CTP-656 tablet confirmed superiority of pharmacokinetic profile relative to Kalydeco ® in Phase I clinical studies
- 1 June 2016
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 15, S22
WS13.6 CTP-656 tablet confirmed superiority of pharmacokinetic profile relative to Kalydeco ® in Phase I clinical studies
- 22 February 2013
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 53 (2) , 140-150
The Pharmacokinetics and Pharmacodynamics of Zaleplon Delivered as a Thermally Generated Aerosol in a Single Breath to Volunteers
Pharmacokinetics, pharmacodynamics, safety, and tolerability of inhaled zaleplon were assessed in healthy volunteers. Forty participants received 0.5, 1, 2, or 4 mg zaleplon or placebo as a thermally generated aerosol in a randomized, double‐blind, parallel‐group, dose escalation study. Blood was collected up to 24 hours after dosing, and sedation was assessed up to 8 hours. Following inhalation, the observed median time to maximum plasma concentrations (25%, 75%) was 1.89 (1.45, 3.08) minutes and the mean (SD) elimination half‐life was 1.24 (0.24) hours. The equilibration half‐life for sedation (t1/2ke0) was 1.16 (0.62, 2.17) minutes. The zaleplon AUC was dose proportional across doses, with a slope (90% confidence interval) of log‐AUC versus log‐dose of 0.92 (0.82, 1.02). No clinically significant changes were noted in laboratory values, vital signs, or spirometry. The most common adverse events were dizziness, somnolence, euphoria, headache, and visual disturbance. Zaleplon inhalation represents a safe, well‐tolerated means of rapidly achieving effective plasma concentrations.
- 22 February 2013
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 53 (2) , 140-150
The Pharmacokinetics and Pharmacodynamics of Zaleplon Delivered as a Thermally Generated Aerosol in a Single Breath to Volunteers
Pharmacokinetics, pharmacodynamics, safety, and tolerability of inhaled zaleplon were assessed in healthy volunteers. Forty participants received 0.5, 1, 2, or 4 mg zaleplon or placebo as a thermally generated aerosol in a randomized, double‐blind, parallel‐group, dose escalation study. Blood was collected up to 24 hours after dosing, and sedation was assessed up to 8 hours. Following inhalation, the observed median time to maximum plasma concentrations (25%, 75%) was 1.89 (1.45, 3.08) minutes and the mean (SD) elimination half‐life was 1.24 (0.24) hours. The equilibration half‐life for sedation (t1/2ke0) was 1.16 (0.62, 2.17) minutes. The zaleplon AUC was dose proportional across doses, with a slope (90% confidence interval) of log‐AUC versus log‐dose of 0.92 (0.82, 1.02). No clinically significant changes were noted in laboratory values, vital signs, or spirometry. The most common adverse events were dizziness, somnolence, euphoria, headache, and visual disturbance. Zaleplon inhalation represents a safe, well‐tolerated means of rapidly achieving effective plasma concentrations.
- 1 August 2010
- Published by SAGE Publications in Journal of Aerosol Medicine and Pulmonary Drug Delivery
- Vol. 23 (4) , 253-260
In Vitro Aerosol Deposition in the Oropharyngeal Region for Staccato ® Loxapine
Background: The Staccato® system employs a thermal vaporization technology to generate pure drug aerosols with a particle size optimized for alveolar deposition, leading to rapid absorption of the drug into the systemic circulation. Unlike most traditional aerosol-generation techniques, the particle size of the thermally generated aerosols is significantly affected by the airflow rate going through the device. The objective of this study was to determine the effects of flow rate and other operating conditions on predicted oropharyngeal and lung deposition when using the Staccato system. Methods: In vitro oropharyngeal deposition was measured at airflow rates of 15–80 L/min through the device. Oropharyngeal deposition was also measured for different inhalation profiles, different ambient temperatures and humidities, and device orientations. Deposition was measured using the Alberta geometry model, which was derived based on information available in the literature, CT scans of patients, and observations of living subjects. Results and Conclusions: Deposition in the oropharyngeal geometry was consistently ∼11% of the emitted dose throughout the entire range of flow rates. Such consistency in deposition was due to the fact that mass median aerodynamic diameter (MMAD) varied inversely as the square root of the flow rate, resulting in an approximately constant value for the inertial deposition parameter. Thus, an increase in flow rate, which would increase the momentum of a fixed particle size and generally lead to higher oropharyngeal deposition, was almost exactly counterbalanced by the accompanying decrease in MMAD. Results also showed that deposition in the oropharyngeal region was unaffected by other potentially relevant factors such as different airflow ramp rates, inhalation time, ambient temperature and relative humidity, and device orientations.
- 1 August 2010
- Published by SAGE Publications in Journal of Aerosol Medicine and Pulmonary Drug Delivery
- Vol. 23 (4) , 253-260
In Vitro Aerosol Deposition in the Oropharyngeal Region for Staccato ® Loxapine
Background: The Staccato® system employs a thermal vaporization technology to generate pure drug aerosols with a particle size optimized for alveolar deposition, leading to rapid absorption of the drug into the systemic circulation. Unlike most traditional aerosol-generation techniques, the particle size of the thermally generated aerosols is significantly affected by the airflow rate going through the device. The objective of this study was to determine the effects of flow rate and other operating conditions on predicted oropharyngeal and lung deposition when using the Staccato system. Methods: In vitro oropharyngeal deposition was measured at airflow rates of 15–80 L/min through the device. Oropharyngeal deposition was also measured for different inhalation profiles, different ambient temperatures and humidities, and device orientations. Deposition was measured using the Alberta geometry model, which was derived based on information available in the literature, CT scans of patients, and observations of living subjects. Results and Conclusions: Deposition in the oropharyngeal geometry was consistently ∼11% of the emitted dose throughout the entire range of flow rates. Such consistency in deposition was due to the fact that mass median aerodynamic diameter (MMAD) varied inversely as the square root of the flow rate, resulting in an approximately constant value for the inertial deposition parameter. Thus, an increase in flow rate, which would increase the momentum of a fixed particle size and generally lead to higher oropharyngeal deposition, was almost exactly counterbalanced by the accompanying decrease in MMAD. Results also showed that deposition in the oropharyngeal region was unaffected by other potentially relevant factors such as different airflow ramp rates, inhalation time, ambient temperature and relative humidity, and device orientations.
- 1 October 2003
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (20) , 3593-3596
Structure–activity relationship studies on 2-heteroaryl-4-arylimidazoles NPY5 receptor antagonists
- 1 October 2003
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (20) , 3593-3596
Structure–activity relationship studies on 2-heteroaryl-4-arylimidazoles NPY5 receptor antagonists
- 1 February 2003
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 46 (5) , 670-673
In Vitro and in Vivo Characterization of 3-{2-[6-(2-tert-Butoxyethoxy)pyridin-3-yl]-1H-imidazol-4-yl}benzonitrile Hydrochloride Salt, a Potent and Selective NPY5 Receptor Antagonist
To investigate the anorectic potential of NPY5 receptor antagonists, we have profiled the in vitro and in vivo properties of 3-{2-[6-(2-tert-butoxyethoxy)pyridin-3-yl]-1H-imidazol-4-yl}benzonitrile hydrochloride salt (1). This compound was found to have excellent NPY5 receptor affinity and selectivity, potent functional antagonism, and good peripheral and central nervous system exposure in rats. This compound attenuated bovine pancreatic polypeptide induced food intake in rats but failed to demonstrate anorectic activity in rodent natural feeding models.
- 1 February 2003
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 46 (5) , 670-673
In Vitro and in Vivo Characterization of 3-{2-[6-(2-tert-Butoxyethoxy)pyridin-3-yl]-1H-imidazol-4-yl}benzonitrile Hydrochloride Salt, a Potent and Selective NPY5 Receptor Antagonist
To investigate the anorectic potential of NPY5 receptor antagonists, we have profiled the in vitro and in vivo properties of 3-{2-[6-(2-tert-butoxyethoxy)pyridin-3-yl]-1H-imidazol-4-yl}benzonitrile hydrochloride salt (1). This compound was found to have excellent NPY5 receptor affinity and selectivity, potent functional antagonism, and good peripheral and central nervous system exposure in rats. This compound attenuated bovine pancreatic polypeptide induced food intake in rats but failed to demonstrate anorectic activity in rodent natural feeding models.